Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271711 · ClinicalTrials.gov registry record · Phase 1
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02271711: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02271711 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02271711, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of expanded natural killer cells in treating younger patients with brain tumors that have come back or do not respond to treatment. Infusing a particular type of a patient's own white blood cells called natural killer cells that have been through a procedure to expand (increase) their numbers may work in treating patients with recurrent/refractory brain tumors.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Natural Killer Cell Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-03-17 |
| Est. Completion | 2020-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02271711
The ClinicalTrials.gov registry entry for NCT02271711 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02271711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02271711 about?
NCT02271711 is a clinical study titled "Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors". This phase I trial studies the side effects and best dose of expanded natural killer cells in treating younger patients with brain tumors that have come back or do not respond to treatment. Infusing a particular type of a patient's own white blood cells called natural killer cells that have been thr...
What is the current status of trial NCT02271711?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-03-17. Estimated completion is 2020-08-28.
What interventions are being tested in trial NCT02271711?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Natural Killer Cell Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT02271711?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.